Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

“…The effectiveness of the 9vHPV vaccine was established in a study involving 45 patients, where the average number of lesions was 15.7. Predominantly, the lesions were situated on the plantar site (57.8%), followed by periungual warts (44.4%) [ 18 ]. The overall complete response rate stood at 62.2%; however, a statistically significant difference surfaced when stratifying the patients by age group.…”

“…The overall complete response rate stood at 62.2%; however, a statistically significant difference surfaced when stratifying the patients by age group. Notably, the response rate was lower in patients aged over 26 years compared to those aged 9 to 26 years (55.0% vs. 84.0%, p = 0.049) [ 18 ]. A younger age (less than 45 years old) emerged as a notable factor, along with a smaller number of lesions (less than 10), a shorter duration of the disease (less than two years), and immunocompetence, collectively enhancing the clinical response to both qHPV and the 9vHPV vaccine, in conjunction with standard treatments ( p > 0.05) [ 9 ].…”

“…These findings highlight that the HPV vaccine demonstrates its highest effectiveness against HPV-related disease outcomes when administered at younger ages, underscoring the crucial importance of timely vaccination [ 60 ]. Moreover, it was established in two of our included studies that vaccine effectiveness, when employed as a treatment, is also contingent on age [ 9 , 18 ].…”

Resolution of extensive plantar verruca vulgaris but not facial verruca plana following nonavalent human papillomavirus vaccine: A case report and literature review

“…A recent open-label study showed a promising response of 62.2% complete clearance by nonavalent HPV vaccine treatment for recalcitrant warts. 5 The proposed mechanism of action of the HPV vaccine is a cross-protective effect evoking a systemic immune response. 5 Furthermore, adjuvant in the vaccine may also activate systemic protection against viral infection by activating nonspecific cellular immunity.…”

“…5 The proposed mechanism of action of the HPV vaccine is a cross-protective effect evoking a systemic immune response. 5 Furthermore, adjuvant in the vaccine may also activate systemic protection against viral infection by activating nonspecific cellular immunity. 1 A previous randomized clinical trial showed that intralesional injection of a quadrivalent HPV vaccine showed a significantly higher proportion of complete clearance than a bivalent vaccine.…”